Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing targeted therapies for genetically driven neuromuscular diseases. Its FORCE platform is designed to deliver therapeutic payloads to muscle tissue and the central nervous system using TfR1-mediated delivery, with programs focused on Duchenne muscular dystrophy, myotonic dystrophy type 1, facioscapulohumeral dystrophy, and Pompe disease.

22.25

22.25

— Dyne Therapeutics, Inc.
%
Clinical-stage product candidates0% Lead therapeutic programs in DM1, DMD, FSHD and Pompe disease advancing through preclinical and clinical development.
FORCE platform technology100% A modular delivery platform that uses TfR1 targeting to transport oligonucleotides, enzymes and other payloads to muscle and CNS.
Preclinical pipeline expansion0% Earlier-stage programs for CNS, rare skeletal muscle, cardiac and metabolic muscle diseases.

Dyne does not yet sell approved products, so its near-term customers are not patients but regulators, clinical...

  • Rare neuromuscular disease patientsprimary

    Patients with genetically driven muscle diseases who would use Dyne's therapies if approved, seeking functional improvement and disease modification.

  • Specialist physiciansprimary

    Neurologists, neuromuscular specialists and metabolic disease physicians who diagnose, prescribe and monitor treatment.

  • Payers and reimbursement authoritiesprimary

    CMS, private insurers and utilization management groups that decide coverage and access for high-cost specialty drugs.

  • Clinical research ecosystemsecondary

    Trial sites, CROs and investigators that execute preclinical and clinical development programs.

  • Potential commercial partnerssecondary

    Biopharma partners that could support development, licensing or commercialization in selected indications.

Dyne is headquartered in the United States and operates as a U.S.-based clinical-stage biotech with global commercial...

  • •Headquartered in the United States
  • •Clinical development and corporate operations are primarily U.S.-based
  • •Global commercial rights to all programs
  • •No product revenue disclosed yet, so no country revenue mix
  • •Future commercialization may require international clinical and regulatory reach

Dyne's strategy is to use its FORCE platform to build a portfolio of differentiated therapies for genetically defined...

01
Advance lead clinical programsshort-term

Clinical proof-of-concept is the main value driver for a pre-revenue biotech and de-risks the platform.

02
Expand FORCE platform applicationsmedium-term

A broader platform can create multiple shots on goal and improve partnering optionality.

03
Secure capital and optional partnershipsshort-term

The company expects continued losses and needs funding to sustain R&D and commercialization readiness.

Dyne is a pre-revenue biotech with significant operating losses, so its business depends on successful clinical...

high

Clinical development failure

Lead programs are still in early stages, and efficacy or safety issues could halt or delay approval.

Scope
DYNE-101, DYNE-251, DYNE-302, DYNE-401
Materiality
high
high

Capital dilution or financing shortfall

The company expects continued losses and will need external funding before product revenue begins.

Scope
Company-wide
Materiality
high
medium

Third-party manufacturing and trial execution

Clinical and manufacturing operations depend on external vendors that can disrupt timelines or raise costs.

Scope
CROs, CMOs, IT and supply chain partners
Materiality
medium
medium

Competitive displacement

Other companies may develop better or earlier therapies for the same rare diseases or delivery problem.

Scope
Neuromuscular disease pipeline
Materiality
medium
medium

Reimbursement and market access

Even approved rare-disease therapies can face restrictive coverage and utilization management.

Scope
Future commercial products
Materiality
medium
Accrued research and development expenses
Can materially shift quarterly operating loss and accrued liabilities
Stock-based compensation
Impacts operating expenses and net loss without affecting cash burn
Future collaboration and milestone revenue
Could create lumpy revenue recognition if partnerships are signed

UNITED THERAPEUTICS Corp

UTHR · Pharmaceutical Preparations

TherapeuticsMD, Inc.

TXMD · Pharmaceutical Preparations

SYNLOGIC, INC.

SYBX · Pharmaceutical Preparations

CAPRICOR THERAPEUTICS, INC.

CAPR · Pharmaceutical Preparations

Quince Therapeutics, Inc.

QNCX · Biological Products, (No Diagnostic Substances)

SOLENO THERAPEUTICS INC

Pharmaceutical Preparations

: 28.4.2026